1. Home
  2. LPSN vs MRKR Comparison

LPSN vs MRKR Comparison

Compare LPSN & MRKR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo LivePerson Inc.

LPSN

LivePerson Inc.

HOLD

Current Price

$1.57

Market Cap

21.6M

Sector

Technology

ML Signal

HOLD

Logo Marker Therapeutics Inc.

MRKR

Marker Therapeutics Inc.

HOLD

Current Price

$1.32

Market Cap

22.5M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
LPSN
MRKR
Founded
1995
1999
Country
United States
United States
Employees
N/A
N/A
Industry
EDP Services
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
21.6M
22.5M
IPO Year
2000
2010

Fundamental Metrics

Financial Performance
Metric
LPSN
MRKR
Price
$1.57
$1.32
Analyst Decision
Hold
Strong Buy
Analyst Count
1
1
Target Price
N/A
$10.00
AVG Volume (30 Days)
86.3K
65.1K
Earning Date
05-06-2026
05-14-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
33.61
EPS
N/A
N/A
Revenue
$249,838,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$936.27
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.39
$0.81
52 Week High
$7.54
$2.46

Technical Indicators

Market Signals
Indicator
LPSN
MRKR
Relative Strength Index (RSI) 29.33 41.15
Support Level $0.39 $1.17
Resistance Level $2.44 $1.54
Average True Range (ATR) 0.08 0.08
MACD -0.01 -0.02
Stochastic Oscillator 2.53 9.09

Price Performance

Historical Comparison
LPSN
MRKR

About LPSN LivePerson Inc.

LivePerson Inc is the enterprise leader in digital customer conversation. The Conversational Cloud, the Companies enterprise-class digital customer conversation platform, is trusted by the brands to accelerate their contact center transformation, orchestrate conversations across all channels, departments, and systems, increase agent productivity, and deliver more personalized, AI-empowered customer experiences. The company has a presence in the United States, Asia-Pacific, Latin America, and Europe.

About MRKR Marker Therapeutics Inc.

Marker Therapeutics Inc is a clinical-stage immuno-oncology company specializing in the development and commercialization of novel T cell-based immunotherapies and peptide-based vaccines for the treatment of hematological malignancies and solid tumor indications. The company develops product candidates from MAR-T cell technology, which is based on the selective expansion of non-engineered, tumor-specific T cells that recognize tumor-associated antigens, or TAAs, which are tumor targets, and then kill tumor cells. These T cells are designed to recognize multiple tumor targets to produce broad spectrum anti-tumor activity. Its pipeline products include: Autologous MAR-T cell product for the treatment of lymphoma and pancreatic cancer (MT-601), and Off-the-Shelf (OTS) products (MT-401-OTS).

Share on Social Networks: